Proactive news snapshot: Ortac Resources, Strategic Minerals, Scancell Holdings…

A glance at some of the day's highlights from the Proactive Investors newswire

Your daily round-up from the world of Proactive

Ortac Resources PLC (LON:OTC)  has reported  further significant new gold assay results taken from the expansion and infill drill programme currently underway at Akyanga.

Shares in Strategic Minerals Plc (LON:SML) shot up in early deals after the miner said its Cobre operations achieved record sales in the fourth quarter. The shares, which closed at 2.10p last night, rose as high as 2.34p as Strategic Minerals said it achieved sales of US$2.14mln during the final quarter of 2017, up from US$2.04mln in the preceding quarter.

Cancer immunotherapy specialist Scancell Holdings Plc (LON:SCLP) has entered into a research collaboration agreement with European biopharma BioNTech as the two look to develop innovative T cell therapies for the treatment of cancer.

Midatech Pharma Plc (LON:MTPH, NASDAQ:MTP) said it had been given the green light by Polish regulators for an EU first-in-human study for Q-Octreotide, also known as MTD201. It has been provided verbal confirmation; formal written approval is expected within the next two weeks.

Metal Tiger PLC (LON:MTR) chief executive Michael McNeilly said that many Kingsgate Consolidated shareholders have supported the AIM-quoted company’s views, even though the result of an EGM vote went against its proposals. The company proposed the replacement of Kingsgate’s management. A total of eight resolutions were voted on, and 34% to 45% of shareholder votes were in Metal Tiger’s favour.

SDX Energy Inc (LON:SDX, CVE:SDX) told investors that it has now put the KSR-16 well, at the Sebou project onshore Morocco, into production. The well yielded a restricted production rate of 8.43mln cubic feet of gas per day, which is the best result of the three recent new wells at the project.

Shareholders in Jubilee Metals Group PLC (LON:JBL) were cheered by news the company has placed shares at a premium to the prevailing market price. Fund manager Miton Group and international wealth firm Veddis have bought shares at 3.6p a pop, raising £4.5mln for Jubilee in the process. The placing includes the issue of 62.5mln warrants with an exercise price 6.12p each.

Allergy Therapeutics plc (LON:AGY) has completed the recruitment to a European phase III clinical trial of its ultra-short course treatment for people allergic to birch pollen. Results from study of PQ Birch are expected in the second half of this year. Researchers will assess the efficacy of the aluminium-free inoculation alongside the safety of the injection.

Waste-to-energy company Powerhouse Energy Group PLC (LON:PHE) said in its full-year business update that its Distributed Modular Gasification system continues to generate significant interest from potential partners.

Workplace software group BOS GLOBAL Holdings Ltd 's (LON:BOS) new board aims to raise £1.2mln to stabilise the balance sheet while it implements a rejuvenation plan. Three new directors have been appointed recently, enough for it to be quorate, and after a review of the business they concluded the existing BOS Time product can be viable with a working capital injection.

Forestry group Obtala Ltd (LON:OBT) is to team up with FundInvest, an investment company, to combat illegal logging and promote timber processing in Mozambique. FundInvest was established by the Ministry of Land, Environment and Rural Development (MITADER) and under the terms of a non-binding memorandum of understanding, will set up a joint venture (JV) with Obtala in which it will own 51%.

Coinsilium Group Limited (NEX:COIN) told investors that it has increased its shareholding in Indorse, a block chain-powered social network for professionals. It is paying just under £100,000 in order to acquire a 3.5% stake, which will increase its shareholding to 6.5%, and under the terms of an option deal the company can acquire a further 3.5% to increase the stake to 10%.

Independent analysis of its 2017 drill programme has confirmed an increase of 180% in the length of the mineralised trend at Amur Minerals Group PLC’s (LON:AMC) Kun-Maine nickel project.

Summit Therapeutics PLC (NASDAQ: SMMT) (AIM: SUMM), the drug discovery and development company advancing therapies for rare diseases and infectious diseases, announced that it will present at the Biotech Showcase(TM), taking place 8-10 January in San Francisco, California. The presentation will take place today, 9 January, at 4:00pm PST.


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Allergy Therapeutics PLC named herein, including the promotion by the Company of Allergy Therapeutics PLC in any Content on the Site, the...



Kazia Therapeutics reaches milestone for Phase 1 Cantrixil trial in ovarian...

Kazia Therapeutics Limited (ASX:KZA) chief executive officer Dr James Garner updates Proactive Investors on a milestone for the company, with the completion of recruitment for Cantrixil its Phase 1 clinical trial in ovarian cancer. The CEO said the first part of the study has shown some very...

1 hour, 30 minutes ago

4 min read